Biocracked
Approach: conceptual metaphor. Palette: D, bold color field.

A single brass pocket-scale balance sits at the center of a saturated mustard-yellow seamless backdrop, shot straight-on from slightly below at eye level. Its two pans hang almost perfectly level. One pan holds a small pile of pale, matte white powder, and the other holds a similar pile, so the tiny, nearly equal difference reads at a glance. A thin electric green thread is tied around the balance's pointer, a subtle accent. Soft, large-window studio light comes from the left and casts a crisp, short shadow to the right on the glossy surface below. Shallow depth of field blurs the background edges. The mood is quiet, skeptical and unresolved, with a clean, editorial look. No text, numerals or markings are visible on the scale.
Longevity

Rapamycin Failed a Huge Human Longevity Test. Here's the Catch

Dr. Synapse · · 4 min read

If you've been following the rapamycin-for-longevity boom, this one stings: the largest real-world look yet at long-term rapamycin exposure in humans found no meaningful lifespan benefit. But before you toss your pill organizer, read the fine print. The people studied are very different from the biohackers experimenting with low, intermittent doses.

The Headline Numbers

In a paper published in Geroscience, Darren Stewart (NYU Langone Health) and William Fitzsimmons (University of Illinois at Chicago) mined US national organ transplant registry data. They compared:

  • 4,885 kidney transplant recipients prescribed rapamycin (an mTOR inhibitor)
  • 6,589 recipients not prescribed rapamycin

Patients were followed for a median of 11 years, and 6,443 died during the study period. All had survived the first year after transplant with a functioning graft.

After propensity score weighting, the median survival age was 64.6 years in the rapamycin group and 64.3 years in the non-rapamycin group. The 95% confidence interval for the difference ran from -1.6 to +2.0 years. The authors concluded they "did not observe a meaningful improvement in long-term survival with mTOR inhibition."

Source: PubMed 42989006 | DOI 10.1007/s11357-026-02643-8

Why This Study Matters

Rapamycin is one of the most talked-about longevity candidates, but the authors note that few human studies exist. Most of the excitement rests on animal work and mechanistic reasoning. This dataset is one of the largest real-world looks at chronic rapamycin exposure in people, with thousands of deaths to analyze rather than a short-term biomarker.

The researchers also adjusted for age, BMI, diabetes and 15 other factors. That matters because people prescribed a drug often differ systematically from those who aren't.

The Big Caveats (Read These Before Drawing Conclusions)

1. This is a transplant population. Everyone in the study had a kidney transplant and a lifetime of immune suppression. Their baseline health, risks and causes of death differ from those of a healthy longevity enthusiast. A drug could plausibly help healthy aging while doing little in this setting.

2. The dosing context is immunosuppressive. In transplant medicine, rapamycin is used to suppress the immune system and protect the graft. That is a different goal from the low-dose, often weekly regimens that longevity users discuss. The paper's abstract doesn't test or support any particular longevity protocol, so don't read it as a verdict on intermittent dosing. The flip side is that it also offers no evidence that intermittent dosing works.

3. It's observational. Propensity weighting reduces measured imbalances but can't remove unmeasured confounding. Patients may be prescribed rapamycin for particular clinical reasons, which could bias results in either direction. This design shows association, not proof of cause and effect.

4. The confidence interval is not tiny. A range of -1.6 to +2.0 years rules out a large benefit or harm but does not rule out a modest effect either way. "No meaningful improvement" is not the same as "proven zero effect."

5. Survivor selection. Only patients alive with a functioning graft at one year were included, so the study says nothing about earlier outcomes.

What It Means for Intermittent-Dosing Longevity Users

Here's the honest read:

  • The optimism took a hit. If rapamycin had a robust, broad lifespan effect in humans, a signal might have shown up in a cohort this big. It didn't, at least in this group.
  • The question isn't settled. The strongest lifespan evidence for rapamycin comes from animal studies (background context, not from this paper). Whether low, intermittent dosing in healthy people changes lifespan or healthspan remains untested in this dataset.
  • Don't extrapolate in either direction. This study neither validates nor debunks off-label longevity regimens.

Practical Takeaways

  • Dose and timing: The paper reports no longevity dose, and no human lifespan-validated dose exists. Anyone considering rapamycin should work with a physician who can monitor them. Don't borrow transplant doses or online protocols blindly.
  • Who it might still interest: Healthy adults curious about geroscience, ideally within a clinical trial or under medical supervision, with realistic expectations that the lifespan benefit is unproven in humans.
  • Who should skip it or be especially careful: Transplant recipients should never change immunosuppression on their own. Anyone with active infections, impaired wound healing or on interacting medications should get medical advice first, since rapamycin affects the immune system and metabolism.
  • Expect a trade-off mindset: Rapamycin is an immune-modulating drug, and the study shows no survival payoff here to offset that.

Bottom Line

This is a sober reality check, not a final verdict. In 11,474 kidney transplant recipients followed for a median of 11 years, rapamycin users and non-users had essentially the same median survival age (64.6 vs 64.3 years). The population, dosing and observational design limit how far the result stretches. For longevity users, the lesson is to hold the hype loosely and wait for randomized trials in healthy people.

The authors report consulting relationships with companies unrelated to this study and declare no competing interests.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Conceptual metaphor: a sheet of thick, clear laboratory glass standing upright, with a single hairline fracture running diagonally across it. A thin ribbon of vivid electric-green liquid seeps through the crack and drips onto a glossy white surface below. The glass is photographed straight on, at a slight low angle, in crisp macro focus along the fracture edges, where tiny chips catch the light. The backdrop is a seamless, saturated tomato-red field that fills the frame. Soft, directional studio light from the left creates bright refraction lines along the glass edge and a clean, warm-red tinted shadow on the right. The mood is tense but revealing, a long-held assumption starting to give way. Empty space on the right balances the composition. No text, no people, and no blue cast.
longevity

Rapamycin 'Can't Reach the Brain'? Why That Myth Is Falling Apart

BY DR. SYNAPSE ·

"Rapamycin can't reach the brain" is one of the most repeated claims in longevity circles, and a new review says it rests on the wrong measurement. The drug is rarely detectable in cerebrospinal fluid, but the authors explain why that doesn't mean it stays out of brain tissue. Human glioblastoma samples, seizure control in tuberous sclerosis, PET scans in Alzheimer's, and blood flow in APOE4 carriers all point to real activity in the brain. The big catch is that nobody has directly measured the drug in healthy human brain tissue at therapeutic doses. Here's what the evidence supports, what it doesn't, and who should think twice.

Approach: conceptual metaphor, in palette D (bold color field).

A saturated mustard-yellow backdrop holds seven identical wooden-handled stopwatches in a staggered row, shot from a slightly raised three-quarter angle. Five stopwatches have run on and show tarnished, cloudy glass faces. The two in front have clean, glossy glass, and each carries a small electric green (#00e676) ribbon tied to its crown. The faces carry no numerals or readable marks. Soft, even studio light from a large overhead softbox gives gentle, short shadows. Shallow depth of field blurs the back of the row. The mood is playful but analytical, with crisp contrast between the dull watches and the bright pair. The image suggests that extra time and good time are not the same thing.
longevity

All 7 Longevity Compounds Extended Lifespan. Only 2 Kept Worms Functional

BY DR. SYNAPSE ·

Seven well-known longevity compounds all extended the lifespan of male roundworms in a new GeroScience study, but only two kept the animals functional late in life. Sulforaphane and metformin were the only treatments that improved late-life mating success, a proxy for reproductive healthspan. The other five added days without preserving that function, showing that lifespan and healthspan can be decoupled. This is strictly worm-only research from C. elegans, not evidence for humans. Still, it argues for screening longevity compounds on function, not survival alone.

Approach: macro science. Palette: bold color field (violet).

Extreme close-up of fisetin crystals, a small cluster of pale yellow needle-like flavonoid crystals with translucent, faceted edges, resting on a smooth glossy deep violet surface. The camera sits low at a shallow three-quarter angle with a very shallow depth of field, so the front crystals are razor sharp and the rest dissolves into soft magenta-violet blur. Lighting is a single crisp, slightly warm studio key from upper left that makes the crystal edges glow and throws long soft shadows across the violet. A few tiny electric green (#00e676) specks of reflected light catch on the crystal tips. The mood is precise, curious and quietly promising, like a sample under inspection, with plenty of clear violet space on the right side of the frame.
longevity

Fisetin Senolytic Extended Mouse Lifespan—Human Proof Still Missing

BY HELIX WARD ·

Fisetin, a plant flavonoid, emerged as the most potent senolytic among ten compounds in a widely cited 2018 EBioMedicine study. In aged mice, treatment late in life reduced senescence markers, eased age-related pathology and extended both median and maximum lifespan. The catch is that this is mouse and lab evidence, not a completed human longevity trial. This article explains what the researchers found, what the dosing context really means, and who should pay attention as human studies develop.

Approach: conceptual metaphor. Palette: bold color field.

A single steel bathroom-style analog tape measure, pulled taut and wrapped around a ripe, glossy yellow-orange pear lying on its side, with the tape's tip locked at the same unmarked point, suggesting a waistline that did not shrink. The pear sits on a saturated magenta seamless backdrop, shot from a low three-quarter angle with a shallow depth of field, the stem sharp and the background softly blurred. Hard but slightly diffused studio key light from upper left casts a crisp, short shadow in deeper magenta on the surface. A tiny electric green sticky dot marks the tape's end, with no numbers or writing visible. Mood: playful, skeptical, deadpan, scientific restraint rather than hype.
longevity

Weekly Rapamycin for a Year: Safe, But Did Visceral Fat Budge?

BY REX MERIDIAN ·

Everyone wants to know whether weekly rapamycin can shrink visceral fat and boost healthspan, and the PEARL trial has an answer that may surprise you. After 48 weeks in healthy adults, the primary endpoint of visceral fat did not budge, yet safety looked comparable to placebo. Some secondary signals, including lean mass and pain in women on 10 mg and better well-being on 5 mg, hint at benefits. But those are subgroup and self-reported findings, the drug was compounded, and no one has shown that it extends human lifespan. Here is what the data supports and what it does not.

This page is available in